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Background: Renal function is a powerful prognostic variable in patients with heart failure (HF). Hospitalisations for acute HF (AHF) may be
associated with further worsening of renal function (WRF).
Methods and results: We analysed the clinical significance of WRF in 318 consecutive patients admitted at our institute for AHF. WRF was
defined as the occurrence, at any time during the hospitalisation, of both a ≥25% and a ≥0.3 mg/dL increase in serum creatinine (s-Cr) from
admission (WRF-Abs-%).
Results: Patients were followed for 480±363 days. Fifty-three patients (17%) died and 132 (41%) were rehospitalised for HF. WRF-Abs-%
occurred in 107 (34%) patients. At multivariable survival analysis, WRF-Abs-% was an independent predictor of death or HF
rehospitalisation (adjusted HR, 1.47; 95%CI, 1.13–1.81; p=0.024). The independent predictors of WRF-Abs-%, evaluated using
multivariable logistic regression, were history of chronic kidney disease (p=0.002), LV ejection fraction (p=0.012), furosemide daily dose
(p=0.03) and NYHA class (p=0.05) on admission.
Conclusion: WRF is a frequent finding in patients hospitalised for AHF and is associated with a poor prognosis. Severity of HF and daily
furosemide dose are the most important predictors of the occurrence of WRF.
© 2008 Published by Elsevier B.V. on behalf of European Society of Cardiology.Keywords: Acute heart failure; Renal function; Prognosis1. Introduction
Renal dysfunction is a frequent finding in patients with
heart failure (HF) and is a powerful independent prognostic
factor for adverse outcomes [1–8]. Its prevalence increases⁎ Corresponding author. Cattedra di Cardiologia, c/o Spedali Civili, Piazza
Spedali Civili, 25100 Brescia, Italy. Tel.: +39 030 3995573; fax: +39 030
3700359.
E-mail address: metramarco@libero.it (M. Metra).
1388-9842/$ - see front matter © 2008 Published by Elsevier B.V. on behalf of E
doi:10.1016/j.ejheart.2008.01.011in patients with more severe HF. More than half of the
patients hospitalised for HF have some degree of impairment
of renal function, and moderate to severe impairment has
been reported in 30–35% of cases [7,9–13]. Hospitalisation
for acute HF is associated with further worsening of renal
function (WRF) in 30–50% of patients, depending on the
specific definition utilized, and this is associated with
prolonged length of hospital stay, increased healthcare
costs, increased in-hospital mortality, and higher rates of
rehospitalisation and death post-discharge [9–11,14–17].uropean Society of Cardiology.
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spective analyses of patients' records from databases of
multiple centers and are often limited to patients≥65 years of
age [9–11,13,15]. With two exceptions [16,17], data on
treatment, an important determinant of renal function
changes, were not available or utilized. The studies also
had relatively short follow-up duration, limited to the in-
hospital course inmany studies [13,15,16] and up to 6months
in others [9,10,17]. Lastly, there is no consensus on how best
to define WRF, with some studies utilizing the absolute [9–
13,15–17] and others using relative [14,18] changes in serum
creatinine (s-Cr) values.
The aim of the present study was to assess the incidence of
WRF, defined as an absolute or relative increase in s-Cr, aswell
as its one-year prognostic value, clinical characteristics and risk
factors in a consecutive series of patients admitted for acuteHF.
2. Methods
2.1. Patients
We prospectively enrolled all qualifying patients admitted
for acute HF at our Institute of Cardiology in Brescia, Italy,
from June 2003 to June 2006. To be included into the study
patients had to satisfy the diagnostic criteria of acute HF, as
established by the European Society of Cardiology guidelines
[19], and require treatment with an intravenous agent, which in
all cases included furosemide with or without other vasoactive
medications. All patients gave their informed written consent
to the protocol, which was approved by the local Ethics
Committee. We excluded patients unable to give informed
consent and those with evidence of acute coronary syndrome,
acute arrhythmia, myocarditis, valve stenosis, cardiac tampo-
nade, aortic dissection, pulmonary embolism, high output
syndrome or evidence of non-cardiovascular factors as main
cause of symptoms. In order to assess the clinical significance
of WRF only when caused by acute HF and/or its treatment,
we also excluded patients who developed complications or
underwent procedures which may cause a rise in s-Cr during
the hospitalisation. Namely, we excluded patients who had
stroke, infection, shock, cardiac arrest, cardiac death or who
underwent cardiac surgery or invasive procedures requiring
contrast administration during the hospitalisation. We also
excluded patients requiring dialysis or ultrafiltration, condi-
tions with a clear prognostic impact in which tubular necrosis
and organic renal damage are often present. Baseline s-Cr was
not an exclusion criterion.
2.2. Investigations
All patients underwent a complete clinical and laboratory
examination at the time of hospital admission, as well as
serial laboratory measurements at 1 to 2 day intervals, and at
hospital discharge. At least one Doppler-echocardiography
exam was performed in all patients 1–3 days before
discharge. Estimated glomerular filtration rate (GFR) wascalculated by the Modification of Diet in Renal Disease
(MDRD) equation. This has been shown to be the best
method for the indirect assessment of renal function in HF
patients [20,21]. Anaemia was defined according to the
criteria of the World Health Organisation, when haemoglo-
bin (Hb) was b13 g/dL in men and b12 g/dL in women [22].
Furosemide doses were determined for: 1) the oral daily dose
prior to hospital admission; 2) the total dose administered
intravenously during the first day of hospitalisation; and 3)
the oral daily dose administered at discharge. Thiazide
diuretics (namely metolazone), dopamine and inotropic
drugs (namely dobutamine or enoximone or levosimendan),
were administered based on clinical indications as judged by
the attending physician. This often occurred when insuffi-
cient diuresis was obtained after furosemide alone, in the
case of thiazide diuretics, and when signs of peripheral
hypoperfusion and/or WRF developed, in the case of
dopamine and/or inotropic agents. Dopamine was always
administered at low doses, as a 2 to 3 μg/kg/min i.v. infusion.
Data collection and end-point adjudication was performed
by independent investigators (GV, CL) who had no role in
patient follow-up and treatment. Follow-up was performed
by periodic (every 3 months) clinical visits and/or telephone
calls to the patient or to her/his physician and her/his
relatives. Relatives were instructed to inform the investiga-
tors as soon as possible, in case of any major cardiovascular
events. Only cardiac death and urgent, unplanned hospita-
lisations were included as end-points of the study.
2.3. Definition of WRF
Worsening renal function was defined based on the
maximal increase in s-Cr from admission to any time during
hospitalisation. The most widely used definition of WRF in
previous studies has been an increase of ≥0.3 mg/dL in s-Cr
[8,10,13,15–17,23]. However, the inverse relationship
between glomerular filtration rate (GFR) and s-Cr is
exponential, so that small changes in s-Cr are attended by
greater reductions in GFR at low initial s-Cr, compared to
higher s-Cr levels [18]. Hence, to correct for the role of
baseline s-Cr, we defined WRF as both a ≥0.3 mg/dL and a
≥25% increase in s-Cr from admission (WRF-Abs-%). Our
definition of WRF was compared to that based only on an
increase in s-Cr≥0.3 mg/dL (WRF-Abs) or≥25% (WRF-%)
from baseline.
2.4. Statistical analyses
The primary objectives of the study were two-fold: first,
to assess the prognostic value of these definitions of WRF,
with respect to the prediction of cardiac death or HF
hospitalisations occurring after discharge, and second, to
assess the variables associated with developing WRF.
Assuming a one-year 50% incidence of major cardiovascular
events (cardiovascular death or HF hospitalisations), we
calculated that a sample size of 320 patients would provide
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change in the risk of these events in the patients with WRF
compared to those without WRF.
Continuous variables were expressed as mean±standard
deviation, unless otherwise specified. Categorical variables
were presented as percentage and compared by Yates
corrected chi-square test. A two-tailed p value b0.05 was
considered significant. Comparisons between groups were
performed by t-test or Wilcoxon test, as appropriate.
Independent predictors of WRF were identified by
multivariable logistic regression analysis with backward
stepwise regression amongst variables assessed prior to
hospitalisation and on admission. All the variables which
were different between patients with and without WRF at
univariable analysis were entered into the initial model. The
only exception was s-Cr on admission which was not entered
in the model for the prediction of WRF, since it was included
in the calculation of the percent change in s-Cr. Variables
were entered at an entry level of significance of pb0.1 and
kept in the model at an exit level of significance of pb0.05.
For descriptive purposes, the analysis was repeated with
continuous variables selected by the multivariable model
dichotomised at their median value.
The combined end-point of cardiovascular mortality or
unplanned HF hospitalisation was used as the primary
outcome end-point. Cumulative event-free survival estimates
were calculated using the Kaplan–Meier method. Patients
were censored at the time of transplantation or of any cardiac
surgical procedure. Differences in survival related to
recognized major risk factors in HF patients [19] were
evaluated by the Log-rank test. Variables which were
different (pb0.1) between patients with and without events
were entered in a multivariable Cox regression model. The
variables assessed were age, gender, body mass index,
systolic blood pressure, heart rate, NYHA class, serum
haemoglobin, creatinine, BUN, and sodium, both on
admission and at discharge, left ventricular (LV) ejection
fraction (EF) and a restrictive pattern of LV filling at
Doppler-echocardiography, treatment with intravenous vaso-
dilator and/or inotropic agents during the hospitalisation,
prescription of angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, beta-blockers, aldosterone
antagonists, digoxin and/or furosemide at discharge, as well
as daily furosemide doses during the hospitalisation and at
discharge. Due to the similarities between the 3 definitions of
WRF and the need to assess their prognostic value, we
repeated the multivariable analysis entering each of the three
definitions of WRF separately.
3. Results
3.1. Patient characteristics
Patient characteristics are listed in Table 1. The mean age
was 68±11 years and 60% were men. A relatively high
percentage of co-morbid conditions were present, including34% of patients with diabetes, 24% with chronic renal
failure, and 42% with anaemia. Left ventricular EF was 34±
15%, with 92 patients (29%) having a LVEF N45%. All the
patients were in New York Heart Association (NYHA) class
III or IVat admission (51%, in class III and 49%, in class IV).
The initial systolic blood pressure was 129±27 mm Hg and
heart rate 80±20 bpm. Pulmonary rales above the bases,
peripheral oedema, signs of increased jugular venous
pressure and hepatomegaly were present in 53%, 61%,
31%, and 40% of the patients, respectively.
Serum creatinine on admission was 1.51±0.84 mg/dL
(range, 0.40 to 9.70 mg/dL; median, interquartile range, [IQR]
1.30, 1.00–1.70 mg/dL); eGFR was 58±29 mL/min (range, 6
to 234 mL/min; median, IQR, 56, 33 to 62 mL/min).
Worsening renal function, defined as a s-Cr increase of both
≥0.3 mg/dL and ≥25% from initial values (WRF-Abs-%)
was found in 107/318 patients (32%) patients, versus 134/318
(42%) and 110/318 (35%) patients when only an increase
≥0.3 mg/dL and an increase ≥25% from baseline, were
considered, respectively.
Table 2 lists the medical treatments of particular interest.
More than 90% of the patients were on furosemide treatment,
both before and after discharge. Seventy-eight percent of the
patients were receiving an inhibitor of the renin–angiotensin
system on entry with no changes at discharge, while there
was an increase in the percentage of patients receiving a beta-
blocker (from 57% to 77%) and an aldosterone antagonist
(from 45% to 55%). With respect to in-hospital treatment, all
patients received i.v. furosemide, 61 patients (21%) received
i.v. vasodilators (nitrates in 59, 19%, and nitroprusside in 21,
7%) and 29 (9%) received inotropic agents (dobutamine and/
or enoximone and/or levosimendan in 18, 6%, 13, 4%, and 5,
2%, patients, respectively).
After the initial hospitalisation, patients were followed for
480±363 days (median, 388). During follow-up, 53 patients
(17%) died and 132 (41%) were hospitalised for HF.
Thirteen additional rehospitalisations occurred for other
cardiovascular reasons (acute coronary syndrome, atrial
fibrillation or stroke) with no signs of HF and were not
considered as end-points. Eleven patients (3.4%) were lost to
follow-up and were excluded from the analysis.
3.2. Characteristics of the patients with WRF
The characteristics of the patients with and without WRF-
Abs-% are compared in Tables 1 and 2. The patients who
developed WRF-Abs-% were more likely to be men and to
have a history of pre-existing renal dysfunction. They also
had more severe HF, as indicated by their more severe
symptoms and signs of HF on admission, and had more
severe impairment of LV systolic function by Doppler-
echocardiography.
Prior to hospital admission, patients who developed
WRF-Abs-% were receiving higher doses of furosemide and
were less likely to be on beta-blockers, consistent with their
more advanced HF. During the hospitalisation, patients who
Table 1
Patients characteristics
Total No WRF-
Abs-%
WRF-
Abs-%
p value
(n=318) (n=211) (n=107)
Demographics
Age, years 68±11 67±12 69±9 0.107
Male, n (%) 190 (60) 117 (55) 73 (68) 0.038
Cause of HF, n (%)
Coronary artery
disease
173 (54) 108 (51) 65 (61)
Idiopathic
cardiomyopathy
120 (38) 84 (40) 36 (34) 0.459
Hypertension 17 (6) 14 (7) 3 (3)
Valvular heart disease 8 (2) 5 (2) 3 (3)
Body weight, kg
Entry 77±15 78±16 76±15 0.266
Discharge 75±15 75±15 74±15 0.275
Δ, entry to discharge −2.22±
2.84
−2.26±
2.84
−2.13±
2.84
0.714
Length of hospital
stay, days
13±11 10±8 17±14 b0.0001
Medical history
Prior heart failure, n, % 185 (58) 118 (56) 67 (63) 0.306
Hypertension, n, % 170 (53) 106 (50) 64 (60) 0.134
Previous MI, n, % 162 (51) 101 (48) 61 (57) 0.155
Diabetes, n, % 91 (29) 59 (30) 32 (30) 0.790
Prior renal failure 78 (25) 40 (19) 38 (36) 0.002
COPD, n, % 45 (14) 25 (12) 20 (19) 0.138
Stroke, n, % 22 (7) 13 (6) 9 (8) 0.608
PVD, n, % 36 (11) 24 (11) 12 (11) 1
Electrocardiogram
QRS duration, ms 130±40 127±39 136±41 0.054
Atrial fibrillation, n, % 98 (31) 57 (27) 41 (38) 0.053
ICD, n, % 89 (28) 52 (25) 37 (35) 0.083
Paced rhythm, n, % 57 (18) 29 (14) 28 (26) 0.010
Clinical presentation
NYHA class
Entry 3.48±
0.50
3.41±
0.49
3.62±
0.49
b0.0001
Discharge 2.04±
0.74
1.95±
0.67
2.22±
0.85
0.002
Systolic BP, mm Hg
Entry 129±27 128±25 131±29 0.316
Discharge 115±18 116±18 115±19 0.557
Diastolic BP, mm Hg
Entry 80±15 79±15 80±16 0.644
Discharge 72±10 72±10 71±10 0.264
Heart rate, bpm
Entry 80±20 79±20 83±20 0.095
Discharge 69±11 68±10 70±11 0.169
Pulmonary rales or
cracklesNbasilar, n (%)
Entry 170 (53) 98 (46) 72 (67) 0.001
Discharge 20 (6) 10 (5) 10 (9) 0.176
Peripheral oedema, n (%)
Entry 107 (34) 58 (27) 49 (46) 0.002
Discharge 6 (2) 2 (1) 4 (4) 0.196
Increased jugular venous
pressure, n (%)
Entry 99 (31) 55 (26) 44 (41) 0.009
Discharge 6 (2) 4 (2) 2 (2) 1.00
Hepatomegaly, n (%)
Entry 126 (40) 82 (39) 44 (41) 0.789
Discharge 19 (6) 11 (5) 8 (7) 0.579
(continued on next page)
Table 1 (continued)
Total No WRF-
Abs-%
WRF-
Abs-%
p value
(n=318) (n=211) (n=107)
Laboratory exams
Haemoglobin, Gm/dL
Entry 13.0±2.0 13.1±2.1 12.9±1.8 0.244
Discharge 12.7±1.94 12.9±2.1 12.4±1.7 0.207
Anaemia, n (%)
Entry 134 (42) 81 (38) 53 (50) 0.007
Discharge 170 (53) 104 (49) 66 (62) 0.048
Creatinine, mg/dL
Entry 1.51±
0.84
1.54±
0.91
1.45±
0.67
0.360
Peak 1.82±
1.05
1.59±
0.98
2.26±
1.06
b0.0001
Discharge 1.55±
0.76
1.39±
0.66
1.88±
0.84
b0.0001
Δ entry to peak,
mg/dL
0.31±
0.54
0.05±
0.20
0.81±
0.62
b0.0001
Δ entry to peak, % 11±23 3±12 62±52 b0.0001
BUN, mg/dL
Entry 67±42 66±44 69±37 0.592
Peak 83±53 74±45 102±61 b0.0001
Discharge 74±44 68±39 89±49 b0.0001
GFR, mL/min
Entry 58±29 56±24 62±37 0.105
Nadir 49±24 55±25 36±10 b0.0001
Discharge 56±26 62±28 45±20 b0.0001
Sodium, mEq/L
Entry 139 ±4 138±4 139±4 0.450
Discharge 139±4 139±4 139±4 0.826
Potassium, mEq/L
Entry 4.1±0.5 4.1±0.6 4.1±0.5 0.133
Discharge 4.2±0.5 4.2±0.5 4.3±0.4 0.102
Uric acid, mg/dL 7.1±2.4 6.9±2.2 7.5±2.7 0.074
Cholesterol,mg/dL 177±44 178±44 174±43 0.398
Troponin I elevation,
n (%)
81 (25) 49 (23) 32 (30) 0.248
Doppler-echocardiography
LV Ejection fraction, % 34.5±
14.6
36.0±
15.0
31.4±
13.2
0.007
Ejection Fractionb45%,
n, %
226 (71) 141 (67) 85 (79) 0.027
LV dilation, % 223 (70) 138 (65) 85 (79) 0.001
Systolic PAPs, mm Hg 44±12 43±11 47±13 0.004
Restrictive LV filling
pattern, n, %
129 (41) 75 (35) 54 (50) 0.015
Mitral regurgitation, n, % 89 (28) 52 (25) 37 (35) 0.083
Inferior vena cava
congestion, n, %
113 (36) 68 (32) 45 (42) 0.108
Abbreviations: ICD, implantable defibrillator; MI, myocardial infarction; LV,
left ventricular; MR, mitral regurgitation; PAP, pulmonary artery pressure;
PVD, peripheral vascular disease; WRF, worsening renal function. Peak refers
to the measurements performed at the time of peak serum creatinine levels.
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furosemide at entry and oral furosemide at discharge, and
were more likely to be treated with i.v. dopamine and/or
inotropic agents.
Using a multivariable model, including baseline clinical
characteristics, co-morbidities, laboratory tests, and con-
comitant treatment, the only independent predictors of
Table 3
Baseline determinants of WRF-Abs-% at multivariable analysis
Predictors Odds ratio (95% CI) p value
Analysis with LVEF and furosemide dose as continuous variables
History of chronic kidney disease 3.66 (1.61–8.33) 0.002
LV ejection fraction 0.97 (0.95–0.99) 0.012
I.v. furosemide daily dose on admission 1.001 (1.000–1.003) 0.034
NYHA class 1.79 (0.99–1.79) 0.052
Analysis with LVEF and furosemide dose as categorical variables
History of chronic kidney disease 1.84 (1.04–3.27) b0.0001
I.v. furosemide dose N100 mg/day 2.18 (1.27–3.73) 0.004
NYHA class (IV versus III) 2.07 (1.24–3.45) 0.005
LV ejection fractionb30% 1.66 (1.01–2.75) 0.047
Table 2
Medical treatment
Total No WRF-Abs-% WRF-Abs-% p value
(n=318) (n=211) (n=107)
Furosemide, n, (%)
Entry 315 (99) 208 (99) 107 (100)
Dose, mg/day 108±149 82±122 160±182 0.532
median (IQR) 50, 25–125 25, 25–75 50, 25–250 0.101
Discharge 290 (91) 188 (89) 102 (91)
Dose, mg/day 100±116 87±111 126±122 b0.001
median (IQR) 50,25–150 50, 25–125 125, 50–250 0.005
ACEi and/or ARBs, n, (%)
Entry 248 (78) 165 (78) 83 (78) 1
Discharge 245 (77) 164 (78) 81 (76) 0.791
Aldosterone antagonists, n, (%)
Entry 143 (45) 94 (46) 49 (45) 0.927
Discharge 185 (55) 117 (64) 68 (58) 0.206
Beta-blockers, n, (%)
Entry 181 (57) 130 (62) 51 (48) 0.024
Discharge 246 (77) 163 (77) 83 (78) 0.364
Digoxin, n, (%)
Entry 98 (31) 64 (30) 34 (32) 0.893
Discharge 99 (31) 61 (29) 38 (36) 0.283
Thiazides, n, (%)
Entry 10 (3) 6 (3) 4 (4) 0.927
Discharge 9 (3) 6 (3) 3 (3) 1
Amlodipine, n, (%)
Entry 20 (6) 10 (5) 10 (9) 0.176
Discharge 19 (6) 13 (6) 6 (6) 1
ASA, n, (%)
Entry 106 (33) 79 (37) 27 (25) 0.040
Discharge 98 (31) 72 (34) 26 (24) 0.096
Ticlopidine/clopidogrel, n, (%)
Entry 62 (20) 41 (19) 21 (20) 1
Discharge 81 (25) 49 (23) 32 (30) 0.248
Warfarin, n, (%)
Entry 56 (18) 30 (14) 26 (24) 0.038
Discharge 52 (16) 26 (12) 26 (24) 0.010
Statins, n, (%)
Entry 117 (37) 80 (37) 37 (37) 0.646
Discharge 143 (45) 95 (45) 48 (45) ns
In-hospital i.v. treatment
I.v. furosemide,
mg/day
190±228 142±180 285±279 b0.001
Entry, mg/day
median, IQR
95, 40–250 50, 25–157 250, 80–500
Vasodilatators,
n,%
67 (21) 38 (18) 29 (27) 0.083
Dopamine, n,% 70 (22) 37 (17) 33 (31) 0.010
Inotropes, n,% 29 (9) 10 (5) 19 (18) b0.001
Fig. 1. Kaplan–Meier HF hospitalisations and cardiovascular mortality free
survival curves for the patients subdivided on the basis ofWRF development,
defined as both ≥0.3 mg/dL and ≥25% s-Cr increase from admission.
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disease, furosemide daily dose on admission, NYHA class,
and LVEF (Table 3). The predictive value of the model for
WRF-Abs-% was, however, low, with a sensitivity of 49%
and a specificity of 74% when furosemide dose and LVEF
were entered as continuous variables and a sensitivity of
41% and a specificity of 70% when they were entered as
categorical variables. Similar results were found when
patients were subdivided on the basis of only an increase
≥0.3 mg/dL (WRF-Abs) or ≥25% (WRF-%) in s-Cr (data
not shown).3.3. Clinical and prognostic significance of WRF
For the group as a whole, the mean duration of
hospitalisation was 11±9 days (median, 7 days; IQR, 6–15).
Patients who developed WRF-Abs-% had a longer mean and
median duration of hospital stay: 15±14 days versus 8±7 days
(median, IQR: 12, 8–22 days versus 8, 5–14, days; pb0.001).
Patients who had developed WRF-Abs-% during the
index hospitalisation had a higher incidence of the combined
end-point of subsequent cardiovascular death and HF
hospitalisations (Fig. 1). Similar increases in the event rate
were also found when patients were subdivided on the basis
of WRF-% and WRF-Abs. In a Cox proportional hazards
multivariable analysis, WRF-Abs-% remained indepen-
dently associated with cardiovascular mortality and HF
hospitalisation (adjusted hazard ratio [HR], 1.47; 95%
confidence intervals [CI], 1.13–1.81; p=0.024). The other
variables found to be significant in the model were peak
193M. Metra et al. / European Journal of Heart Failure 10 (2008) 188–195furosemide dose administered during hospitalisation
(pb0.001), body weight decrease during hospitalisation
(p=0.001), systolic blood pressure at discharge (p=0.002),
diabetes (p=0.012), a restrictive pattern of LV filling at pre-
discharge Doppler-echocardiography (p=0.012), and serum
haemoglobin levels (p=0.037). Similar results were obtained
with WRF-%. In contrast, when WRF was defined only on
the basis of an increase in s-Cr≥0.3 mg/dL, it was no longer
a statistically significant independent predictor of outcome in
the multivariable analysis. The other variables remained
significant predictors, with the addition of BUN at discharge
(p=0.076).
Subgroup analysis showed that WRF-Abs-% was asso-
ciated with an increased event rate in all the subgroups
without significant interactions based on either baseline
clinical characteristics, parameters of LV systolic function or
concomitant treatment.
4. Discussion
4.1. Patient characteristics
Our study confirms previous reports of the high
prevalence of WRF in patients hospitalised for acute HF
and its important impact on hospital length of stay and
prognosis [9–11,13–17]. Our study differs from most of the
previous studies, however, in that this was a prospectively
designed single center protocol. Our patients had the
characteristics of patients treated by a tertiary care HF
center, i.e. they tended to be slightly younger, were less
likely to be women, had a higher prevalence of previous HF
and a lower LVEF, compared to the patients enrolled in some
[10–12] but not other [13–17] previous larger studies,
several of which included only patients ≥65 years. The
prevalence of concomitant diseases and, namely, of previous
chronic renal failure as well as the s-Cr, BUN and eGFR
values on admission of our patients were similar to those in
previous studies [5,9–17].
4.2. Prevalence of WRF
We used a different definition of WRF, which included
not only the absolute increase in s-Cr from values on
admission but also required a 25% increase. This is
important and, we believe, more appropriate since the
same increase in s-Cr is, in fact, accompanied by a greater
decline in GFR when it occurs from a low initial value [18].
Our definition, based on both absolute and percent s-Cr
changes, yielded a lower incidence of WRF (107/318
patients, 32%) compared to the more traditional definition
of WRF (i.e. an increase of s-Cr ≥0.3 mg/dL), which was
present in 134/318 patients (42%) in our study. Similar
results were found when WRF was defined based on a
≥25% increase in s-Cr. We believe that our study shows the
greater clinical and prognostic value of WRF-Abs-% and
WRF-% compared to a definition based only on the absoluteincrease in s-Cr. The small size of our study group does not
allow us to establish whether WRF-Abs-% is better than
WRF-% only.
We found an incidence of WRF which was slightly higher
than that reported in many [9–11,14,15] but not all [13,17]
previous studies. This difference is likely caused by our
protocol with frequent (every 1–2 days) reassessments of s-
Cr as well as by the higher prevalence of patients with
advanced HF. Our study highlights the importance of
frequent reassessments of renal function as the detection of
WRF had prognostic significance.
4.3. Causes of WRF
The mechanisms which may cause WRF in patients with
HF are multiple and are incompletely understood [6,24].
They include neurohormonal activation, decreased renal
perfusion, and intrarenal mechanisms involving increased
endothelin and/or adenosine release. Medical treatment may
also have a significant role. In our study, daily intravenous
furosemide dose, history of chronic kidney disease, NYHA
class and LVEF were independent predictors of WRF.
Consistent with our data, the only other study in which the
relationship of in-hospital medical treatment to subsequent
WRF was assessed, also found that high doses of furosemide
were associated with more frequent WRF [16]. Furosemide
treatment, especially if at high doses, has been associated
with a worse prognosis [25–28] andWRF may be a potential
mechanism. On the other hand, we cannot exclude the
possibility that the administration of higher doses of
furosemide is a consequence, rather than a cause, of more
advanced HF and coexistent renal failure. In this case, this
would just be a marker, rather than a mechanism for poor
outcomes. It is noteworthy that signs of congestion were
more frequent in patients with WRF, whereas the actual
decline in body weight was similar. This suggests that the
patients had developed resistance to furosemide rather than
having been subjected to excessive diuresis.
Diabetes [15–17], elevated systolic blood pressure
[10,15,16], a history of HF [15,16] tachycardia and female
gender [10] were all factors associated with increased risk of
WRF in previous studies but this was not the case in our
study. These differences are likely related to our smaller and
more selected study group, such that some differences (e.g.
history of HF) did not reach statistical significance and co-
morbidities were less important. Diabetes was, however, a
significant determinant of subsequent mortality and
hospitalisations.
4.4. Clinical and prognostic value of WRF
The length of hospital stay of our patients was comparable
to that found in other European registries [29–32]. Our
patients who developed WRF had a longer duration of
hospital stay and this may be important both with respect to
quality of life and the cost of treatment. Increased length of
194 M. Metra et al. / European Journal of Heart Failure 10 (2008) 188–195hospital stay is likely an effect of WRF as it causes changes
in treatment aimed at improving renal function. Consistently,
s-Cr values at discharge were also lower than peak ones in
our patients who developed WRF.
Worsening renal function was an independent predictor of
subsequent mortality and HF hospitalisations. The other
variables selected in our multivariable model were systolic
blood pressure at discharge, body weight decrease during
hospitalisation, diabetes, serum haemoglobin levels, peak
furosemide dose during hospitalisation, and persistence of a
restrictive pattern of LV filling at pre-discharge Doppler-
echocardiography. These results are consistent with recent
studies of prognostic variables in HF patients, both with
regard to the variables selected and to the magnitude of their
effect [27,32,33–36]. Renal function was significantly
different in the patients with major cardiovascular events,
compared to the others. However, when WRF-Abs-% was
entered into our model, it lost its significance.
WRF-Abs has been shown to be associated with a poor
prognosis in most [9–11,13–16] but not all [17] of the
previous studies. Some of these studies, however, did not
assess the prognostic value of WRF compared with other
variables by multivariable analysis [11,13,14]. Our results
are consistent with those of Cowie et al. who found that an
increase in s-Cr by 0.3 mg/dL is associated with a poor
prognosis in univariate, but not multivariable analysis [17].
WRF-Abs-%, unlike WRF-Abs, remained significantly
related to prognosis after adjustment for the other variables.
This difference is likely related to the exponential relation
between s-Cr and GFR so that WRF, expressed as both an
absolute and a percentage change, also takes into account
initial s-Cr values [18].
4.5. Limitations of the study
Our study is limited by the relatively low number of
patients and events. It is likely that a larger study group with
a greater number of events would have allowed the
identification of an independent prognostic role of other
variables such as, for instance, serum creatinine at discharge.
However, as pointed out by the statistical power calculation,
the size of our group was sufficient to detect a significant
association between WRF and outcomes, which was the
primary aim of our study.
Another limitation may be found in the possibility of biases
during follow-up favouring rehospitalisations in the patients
who had developedWRF during the initial hospitalisation and
vice versa. However, only urgent, unplanned hospitalisations
were included as end-points and these events have a low
likelihood to be influenced by the investigator.
5. Conclusions
Our study demonstrates that WRF is a common finding in
patients hospitalised for acute HF. Patients who developed
WRF were more likely to have a history of chronic kidneydisease, had more severe HF and were treated with higher
doses of furosemide. When defined as both an absolute and a
percent increase from baseline, WRF is an especially
powerful and independent predictor of subsequent cardio-
vascular mortality and HF hospitalisations.
References
[1] Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The
prognostic implications of renal insufficiency in asymptomatic and
symptomatic patients with left ventricular systolic dysfunction. J Am
Coll Cardiol 2000;35:681–9.
[2] Hillege HL,Girbes AR, de KamPJ, et al. Renal function, neurohormonal
activation, and survival in patients with chronic heart failure. Circulation
2000;102:203–10.
[3] Mahon NG, Blackstone EH, Francis GS, Starling III RC, Young JB,
Lauer MS. The prognostic value of estimated creatinine clearance
alongside functional capacity in ambulatory patients with chronic
congestive heart failure. J Am Coll Cardiol 2002;40(6):1106–13.
[4] Shlipak MG, Smith GL, Rathore SS, Massie BM, Krumholz HM.
Renal function, digoxin therapy, and heart failure outcomes: evidence
from the digoxin intervention group trial. J Am Soc Nephrol
2004;15:2195–203.
[5] McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal
insufficiency and heart failure: prognostic and therapeutic implications
from a prospective cohort study. Circulation 2004;109:1004–9.
[6] Shlipak MG, Massie BM. The clinical challenge of cardiorenal
syndrome. Circulation 2004;110:1514–7.
[7] Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and
outcomes in heart failure: systematic review and meta-analysis. J Am
Coll Cardiol 2006;47:1987–96.
[8] de Silva R, Nikitin NP, Witte KK, et al. Incidence of renal dysfunction
over 6 months in patients with chronic heart failure due to left
ventricular systolic dysfunction: contributing factors and relationship
to prognosis. Eur Heart J 2006;27:569–81.
[9] Akhter MW, Aronson D, Bitar F, et al. Effect of elevated admission
serum creatinine and its worsening on outcome in hospitalized patients
with decompensated heart failure. Am J Cardiol 2004;94:957–60.
[10] Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on
outcomes of worsening renal function in patients N or =65 years of age
with heart failure. Am J Cardiol 2000;85:1110–3.
[11] Smith GL, Vaccarino V, Kosiborod M, et al. Worsening renal function:
what is a clinically meaningful change in creatinine during
hospitalization with heart failure? J Card Fail 2003;9:13–25.
[12] van Kimmenade RRJ, Januzzi Jr JL, Baggish AL, et al. Amino-
terminal pro-brain natriuretic peptide, renal function, and outcomes in
acute heart failure: redefining the cardiorenal interaction? J Am Coll
Cardiol 2006;48:1621–7.
[13] Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of
different definitions of worsening renal function in congestive heart
failure. J Card Fail 2002;8:136–41.
[14] Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal
dysfunction during intensive therapy for advanced chronic heart
failure. Am Heart J 1999;138:285–90.
[15] Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission,
and impact of worsening renal function among patients hospitalized
with heart failure. J Am Coll Cardiol 2004;43:61–7.
[16] Butler J, Forman DE, Abraham WT, et al. Relationship between heart
failure treatment and development of worsening renal function among
hospitalized patients. Am Heart J 2004;147:331–8.
[17] Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B.
Prevalence and impact of worsening renal function in patients
hospitalized with decompensated heart failure: results of the
prospective outcomes study in heart failure (POSH). Eur Heart J
2006;27:1216–22.
195M. Metra et al. / European Journal of Heart Failure 10 (2008) 188–195[18] Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney
function-measured and estimated glomerular filtration rate. N Engl J
Med 2006;354:2473–83.
[19] Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the
guidelines on the diagnosis and treatment of acute heart failure: the
Task Force on Acute Heart Failure of the European Society of
Cardiology. Eur Heart J 2005;26:384–416.
[20] O'meara E, Chong KS, Gardner RS, Jardine AG, Neilly JB,
McDonagh TA. The Modification of Diet in Renal Disease (MDRD)
equations provide valid estimations of glomerular filtration rates in
patients with advanced heart failure. Eur J Heart Fail 2006;8:63–7.
[21] Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL.
Drawbacks and prognostic value of formulas estimating renal function
in patients with chronic heart failure and systolic dysfunction.
Circulation 2006;114:1572–80.
[22] Izaks GJ, Westendorp RG, Knook DL. The definition of anemia in
older persons. JAMA 1999;281:1714–7.
[23] Pitt B, Segal R, Martinez FA, Meurers G, et al. Randomised trial of
losartan versus captopril in patients over 65 with heart failure
(Evaluation of Losartan in the Elderly Study, ELITE). Lancet
1997;349:747–52.
[24] Lapman PG, Golduber GN, Le Jemtel TH. Heart failure treatment and
renal function. Am Heart J 2004;147:193–4.
[25] Neuberg GW, Miller AB, O'Connor CM, et al. Diuretic resistance
predicts mortality in patients with advanced heart failure. Am Heart J
2002;144:31–8.
[26] Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose
to mortality in advanced heart failure. Am J Cardiol 2006;97:1759–64.
[27] Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure
Model: prediction of survival in heart failure. Circulation 2006;113:
1424–33.[28] Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose
of loop diuretics and outcomes in a heart failure population: results of
the ESCAPE trial. Eur J Heart Fail 2007;9:1064–9.
[29] Rudiger A, Harjola VP, Muller A, et al. Acute heart failure: clinical
presentation, one-year mortality and prognostic factors. Eur J Heart
Fail 2005;7:662–70.
[30] Zannad F, Mebazaa A, Juilliére Y, et al. Clinical profile, contemporary
management and one-year mortality in patients with severe acute heart
failure syndromes: the EFICA study. Eur J Heart Fail 2006;8:697–705.
[31] Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure
Survey II (EHFS II): a survey on hospitalized acute heart failure
patients: description of population. Eur Heart J 2006;27:2725–36.
[32] Tavazzi L, Maggioni AP, Lucci D, et al. Nationwide survey on acute
heart failure in cardiology ward services in Italy. Eur Heart J
2006;27:1207–15.
[33] Aronson D, Mittleman MA, Burger AJ. Elevated blood urea nitrogen
level as a predictor of mortality in patients admitted for decompensated
heart failure. Am J Med 2004;116:466–73.
[34] Fonarow GC, Adams Jr KF, Abraham WT, Yancy CW, Boscardin WJ.
ADHERE Scientific Advisory Committee, Study Group, and Inves-
tigators. risk stratification for in-hospital mortality in acutely
decompensated heart failure: classification and regression tree analysis.
JAMA 2005;293:572–80.
[35] Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and
morbidity in patients with chronic heart failure. Eur Heart J
2006;27:65–75.
[36] Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood
pressure at admission, clinical characteristics, and outcomes in patients
hospitalized with acute heart failure. JAMA 2006;296:2217–26.
